JP2015520738A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520738A5 JP2015520738A5 JP2015509412A JP2015509412A JP2015520738A5 JP 2015520738 A5 JP2015520738 A5 JP 2015520738A5 JP 2015509412 A JP2015509412 A JP 2015509412A JP 2015509412 A JP2015509412 A JP 2015509412A JP 2015520738 A5 JP2015520738 A5 JP 2015520738A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- compound
- carbonyl
- amino
- prop
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 69
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 40
- 229910052739 hydrogen Inorganic materials 0.000 claims description 39
- 239000001257 hydrogen Substances 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 38
- 239000012453 solvate Substances 0.000 claims description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 229910052731 fluorine Inorganic materials 0.000 claims description 14
- 239000011737 fluorine Chemical group 0.000 claims description 14
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 239000000460 chlorine Chemical group 0.000 claims description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 150000002431 hydrogen Chemical group 0.000 claims description 5
- 229910052794 bromium Chemical group 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims 3
- DUDRGGQIZWNEAX-BUHFOSPRSA-N (e)-3-[3-[(3-phenylnaphthalene-1-carbonyl)amino]phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C=CC=CC=2)=C1 DUDRGGQIZWNEAX-BUHFOSPRSA-N 0.000 claims 2
- MLTFSGKJMAZYPD-ACCUITESSA-N (e)-3-[4-fluoro-3-[(3-phenylnaphthalene-1-carbonyl)amino]phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(F)C(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C=CC=CC=2)=C1 MLTFSGKJMAZYPD-ACCUITESSA-N 0.000 claims 2
- SDXGEFXEIZKNLU-ZRDIBKRKSA-N (e)-3-[4-fluoro-3-[[3-(2-fluorophenyl)naphthalene-1-carbonyl]amino]phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(F)C(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C(=CC=CC=2)F)=C1 SDXGEFXEIZKNLU-ZRDIBKRKSA-N 0.000 claims 2
- SZJANXQTMCKGEL-PKNBQFBNSA-N (e)-3-[4-fluoro-3-[[3-(3-fluorophenyl)naphthalene-1-carbonyl]amino]phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(F)C(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C=C(F)C=CC=2)=C1 SZJANXQTMCKGEL-PKNBQFBNSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- DKZILSZEHXVPQA-CMDGGOBGSA-N (e)-3-[3-[(3-morpholin-4-ylnaphthalene-1-carbonyl)amino]phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(NC(=O)C=2C3=CC=CC=C3C=C(C=2)N2CCOCC2)=C1 DKZILSZEHXVPQA-CMDGGOBGSA-N 0.000 claims 1
- PAUFDURBIMGZNV-VAWYXSNFSA-N (e)-3-[3-[[3-(3-hydroxyphenyl)naphthalene-1-carbonyl]amino]phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C=C(O)C=CC=2)=C1 PAUFDURBIMGZNV-VAWYXSNFSA-N 0.000 claims 1
- DSWUIKWSKLOGQW-VAWYXSNFSA-N (e)-3-[3-[[3-(3-piperazin-1-ylphenyl)naphthalene-1-carbonyl]amino]phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C=C(C=CC=2)N2CCNCC2)=C1 DSWUIKWSKLOGQW-VAWYXSNFSA-N 0.000 claims 1
- CWDKEJJCKWQNRU-ZRDIBKRKSA-N (e)-3-[3-[[3-[3-(acetamidomethyl)phenyl]naphthalene-1-carbonyl]amino]-4-fluorophenyl]prop-2-enoic acid Chemical compound CC(=O)NCC1=CC=CC(C=2C=C3C=CC=CC3=C(C(=O)NC=3C(=CC=C(\C=C\C(O)=O)C=3)F)C=2)=C1 CWDKEJJCKWQNRU-ZRDIBKRKSA-N 0.000 claims 1
- GBPDOTSQVLSVHZ-PKNBQFBNSA-N (e)-3-[3-[[3-[3-(aminomethyl)phenyl]naphthalene-1-carbonyl]amino]-4-fluorophenyl]prop-2-enoic acid Chemical compound NCC1=CC=CC(C=2C=C3C=CC=CC3=C(C(=O)NC=3C(=CC=C(\C=C\C(O)=O)C=3)F)C=2)=C1 GBPDOTSQVLSVHZ-PKNBQFBNSA-N 0.000 claims 1
- LDGPNDLWSAZALF-BUHFOSPRSA-N (e)-3-[3-[[3-[3-(dimethylcarbamoyloxy)phenyl]naphthalene-1-carbonyl]amino]phenyl]prop-2-enoic acid Chemical compound CN(C)C(=O)OC1=CC=CC(C=2C=C3C=CC=CC3=C(C(=O)NC=3C=C(\C=C\C(O)=O)C=CC=3)C=2)=C1 LDGPNDLWSAZALF-BUHFOSPRSA-N 0.000 claims 1
- YSGFFHLAKKDUGX-ACCUITESSA-N (e)-3-[4-chloro-3-[(3-phenylnaphthalene-1-carbonyl)amino]phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(Cl)C(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C=CC=CC=2)=C1 YSGFFHLAKKDUGX-ACCUITESSA-N 0.000 claims 1
- RYAVEENVEHIVNZ-PKNBQFBNSA-N (e)-3-[4-fluoro-3-[(3-piperidin-1-ylnaphthalene-1-carbonyl)amino]phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(F)C(NC(=O)C=2C3=CC=CC=C3C=C(C=2)N2CCCCC2)=C1 RYAVEENVEHIVNZ-PKNBQFBNSA-N 0.000 claims 1
- YRENBPWEOGTVIG-SOFGYWHQSA-N (e)-3-[4-fluoro-3-[[3-(3-fluoro-5-hydroxyphenyl)naphthalene-1-carbonyl]amino]phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(F)C(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C=C(F)C=C(O)C=2)=C1 YRENBPWEOGTVIG-SOFGYWHQSA-N 0.000 claims 1
- MXTBYSCJAKHIGH-WUXMJOGZSA-N (e)-3-[4-fluoro-3-[[3-(4-fluorophenyl)naphthalene-1-carbonyl]amino]phenyl]prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=C(F)C(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C=CC(F)=CC=2)=C1 MXTBYSCJAKHIGH-WUXMJOGZSA-N 0.000 claims 1
- JVUKNURXFSUMAK-ZRDIBKRKSA-N (e)-3-[4-fluoro-3-[[3-[2-(hydroxymethyl)phenyl]naphthalene-1-carbonyl]amino]phenyl]prop-2-enoic acid Chemical compound OCC1=CC=CC=C1C1=CC(C(=O)NC=2C(=CC=C(\C=C\C(O)=O)C=2)F)=C(C=CC=C2)C2=C1 JVUKNURXFSUMAK-ZRDIBKRKSA-N 0.000 claims 1
- KTXLSTXIYHGVLQ-PKNBQFBNSA-N (e)-3-[4-fluoro-3-[[3-[3-(hydroxymethyl)phenyl]naphthalene-1-carbonyl]amino]phenyl]prop-2-enoic acid Chemical compound OCC1=CC=CC(C=2C=C3C=CC=CC3=C(C(=O)NC=3C(=CC=C(\C=C\C(O)=O)C=3)F)C=2)=C1 KTXLSTXIYHGVLQ-PKNBQFBNSA-N 0.000 claims 1
- XDAOUWZAESZPAW-UHFFFAOYSA-N 2-[3-[(3-phenylnaphthalene-1-carbonyl)amino]phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=CC(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C=CC=CC=2)=C1 XDAOUWZAESZPAW-UHFFFAOYSA-N 0.000 claims 1
- SICRZVWWEUZPMH-UHFFFAOYSA-N 2-[4-chloro-3-[(3-phenylnaphthalene-1-carbonyl)amino]phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C=CC=CC=2)=C1 SICRZVWWEUZPMH-UHFFFAOYSA-N 0.000 claims 1
- KZSCWGKVHMLCCP-UHFFFAOYSA-N 2-[4-fluoro-3-[(3-phenylnaphthalene-1-carbonyl)amino]phenoxy]acetic acid Chemical compound OC(=O)COC1=CC=C(F)C(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C=CC=CC=2)=C1 KZSCWGKVHMLCCP-UHFFFAOYSA-N 0.000 claims 1
- XAGWIFNYWJOQTH-UHFFFAOYSA-N 3-[3-[(3-phenylnaphthalene-1-carbonyl)amino]phenyl]propanoic acid Chemical compound OC(=O)CCC1=CC=CC(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C=CC=CC=2)=C1 XAGWIFNYWJOQTH-UHFFFAOYSA-N 0.000 claims 1
- AHLNKSMQDJIKNG-UHFFFAOYSA-N 3-[4-fluoro-3-[(3-phenylnaphthalene-1-carbonyl)amino]phenyl]propanoic acid Chemical compound OC(=O)CCC1=CC=C(F)C(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C=CC=CC=2)=C1 AHLNKSMQDJIKNG-UHFFFAOYSA-N 0.000 claims 1
- ZUQFNZSXRZUAFY-UHFFFAOYSA-N 3-[4-fluoro-3-[[3-(2-fluorophenyl)naphthalene-1-carbonyl]amino]phenyl]propanoic acid Chemical compound OC(=O)CCC1=CC=C(F)C(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C(=CC=CC=2)F)=C1 ZUQFNZSXRZUAFY-UHFFFAOYSA-N 0.000 claims 1
- WTVMTOYEUACEKQ-UHFFFAOYSA-N 3-[4-fluoro-3-[[3-(3-fluorophenyl)naphthalene-1-carbonyl]amino]phenyl]propanoic acid Chemical compound OC(=O)CCC1=CC=C(F)C(NC(=O)C=2C3=CC=CC=C3C=C(C=2)C=2C=C(F)C=CC=2)=C1 WTVMTOYEUACEKQ-UHFFFAOYSA-N 0.000 claims 1
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 101800000734 Angiotensin-1 Proteins 0.000 claims 1
- 102400000344 Angiotensin-1 Human genes 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- 102000000536 PPAR gamma Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000010085 airway hyperresponsiveness Effects 0.000 claims 1
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003510 anti-fibrotic effect Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 208000023819 chronic asthma Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 239000000938 histamine H1 antagonist Substances 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 239000003580 lung surfactant Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000009325 pulmonary function Effects 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229960000278 theophylline Drugs 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
- 229940046008 vitamin d Drugs 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- -1 (dimethylcarbamoyl) oxy, acetylaminomethyl Chemical group 0.000 description 1
- 0 CN1CC*CC1 Chemical compound CN1CC*CC1 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1379/MUM/2012 | 2012-05-03 | ||
| IN1379MU2012 | 2012-05-03 | ||
| EP12172673 | 2012-06-20 | ||
| EP12172673.1 | 2012-06-20 | ||
| PCT/EP2013/058947 WO2013164326A1 (en) | 2012-05-03 | 2013-04-30 | Novel ep2 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520738A JP2015520738A (ja) | 2015-07-23 |
| JP2015520738A5 true JP2015520738A5 (enExample) | 2016-06-09 |
| JP6120951B2 JP6120951B2 (ja) | 2017-04-26 |
Family
ID=48485111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015509412A Active JP6120951B2 (ja) | 2012-05-03 | 2013-04-30 | 新規ｅｐ２受容体作動薬 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9309187B2 (enExample) |
| EP (1) | EP2844638A1 (enExample) |
| JP (1) | JP6120951B2 (enExample) |
| CN (1) | CN104507906B (enExample) |
| CA (1) | CA2867527A1 (enExample) |
| WO (1) | WO2013164326A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10189788B2 (en) | 2014-09-09 | 2019-01-29 | Bayer Pharma Aktiengesellschaft | Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
| EP3271334A1 (de) | 2015-03-18 | 2018-01-24 | Bayer Pharma Aktiengesellschaft | Substituierte n-bicyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
| WO2017153235A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung |
| WO2017153231A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung |
| WO2017153234A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
| TWI770157B (zh) | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
| BR112019021136A2 (pt) | 2017-04-10 | 2020-07-21 | Bayer Aktiengesellschaft | n-ariletil-2-arilquinolina-4-carboxamidas substituídas e uso das mesmas |
| TW202114985A (zh) * | 2019-06-28 | 2021-04-16 | 日商小野藥品工業股份有限公司 | Ｅｐ拮抗劑 |
| TW202241846A (zh) * | 2020-12-24 | 2022-11-01 | 日商小野藥品工業股份有限公司 | 具有ｅｐ拮抗活性之化合物的鹽、溶劑合物及結晶 |
| JP2024016314A (ja) * | 2020-12-24 | 2024-02-07 | 小野薬品工業株式会社 | 一般式（ｉ－ａ）で示される化合物、その薬学的に許容される塩、またはそれらの水和物と免疫チェックポイント阻害薬および／またはｅｐ４受容体拮抗薬との組み合わせ |
| JP2024016311A (ja) * | 2020-12-24 | 2024-02-07 | 小野薬品工業株式会社 | Ｅｐ２アンタゴニスト |
| CN114805112A (zh) * | 2022-05-31 | 2022-07-29 | 常州大学 | 一种pde2抑制剂酰胺类衍生物及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005080367A1 (en) * | 2004-02-12 | 2005-09-01 | Pharmagene Laboratories Limited | Ep2 receptor agonists |
| US8080567B2 (en) * | 2005-08-09 | 2011-12-20 | Asterand Uk Limited | EP2 receptor agonists |
| CN101495452B (zh) | 2006-07-28 | 2012-04-25 | 辉瑞产品公司 | Ep2激动剂 |
| JP4583500B2 (ja) | 2006-07-28 | 2010-11-17 | ファイザー・プロダクツ・インク | Ｅｐ２作動薬 |
| BRPI0907522A2 (pt) | 2008-02-05 | 2019-09-24 | Asterand Uk Ltd | biarlamidas |
-
2013
- 2013-04-30 EP EP13724745.8A patent/EP2844638A1/en not_active Withdrawn
- 2013-04-30 CN CN201380023227.1A patent/CN104507906B/zh not_active Expired - Fee Related
- 2013-04-30 CA CA2867527A patent/CA2867527A1/en not_active Abandoned
- 2013-04-30 JP JP2015509412A patent/JP6120951B2/ja active Active
- 2013-04-30 US US14/397,319 patent/US9309187B2/en not_active Expired - Fee Related
- 2013-04-30 WO PCT/EP2013/058947 patent/WO2013164326A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015520738A5 (enExample) | ||
| JP2017515844A5 (enExample) | ||
| JP2015514060A5 (enExample) | ||
| JP2012507535A5 (enExample) | ||
| JP2007529486A5 (enExample) | ||
| JP2014513110A5 (enExample) | ||
| JP2017528503A5 (enExample) | ||
| TNSN08104A1 (en) | Pyrimidine amide compounds as pgds inhibitors | |
| MY154895A (en) | Pyrimidine hydrazide compounds as pgds inhibitors | |
| JP2008505171A5 (enExample) | ||
| NO20051540L (no) | 2,5-dioksoimidazolidin-4-yl acetamider og analoger som inhibitorer av metalloproteinas MMP12 | |
| JP2018509438A5 (enExample) | ||
| JP2014037426A5 (enExample) | ||
| JP2015516000A5 (enExample) | ||
| NZ566788A (en) | Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation | |
| JP2016534063A5 (enExample) | ||
| JP2017522348A5 (enExample) | ||
| JP2009526037A (ja) | トリアゾロピリジン化合物 | |
| JP2012523440A5 (enExample) | ||
| JP2009525956A5 (enExample) | ||
| JP2009543795A5 (enExample) | ||
| JP2016518317A5 (enExample) | ||
| JP2009514910A5 (enExample) | ||
| JP2016529306A5 (enExample) | ||
| JP2018507223A5 (enExample) |